Extensively drug-resistant *Myroides odoratimimus* – a case series of urinary tract infections in immunocompromised patients

Monica Licker1,2, Teodora Sorescu3,4, Maria Rus5,6, Natalia Cîrliea6, Florin Horhat1, Cristiana Jurescu5,6, Mircea Botoca7,8, Alin Cumpânaș7,8, Romulus Timar3,4, Delia Muntean1,2

1Department of Microbiology, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania; 2Clinical Laboratory, “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, Romania; 3Department of Internal Medicine II, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania; 4“Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania; 5Diabetes Clinic, “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, Romania; 6Department of Orthopaedics – Traumatology, Urology and Medical Imaging, “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania; 7Urology Unit, “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, Romania; 8Department of Urology and Medical Imaging, “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, Romania

Correspondence: Teodora Sorescu
“Victor Babeș” University of Medicine and Pharmacy, Eftimie Murgu 2, Timișoara 300041, Romania
Tel +40 72 451 5424
Fax +40 25 622 0484
Email sorescu.teodora@umft.ro

**Purpose:** We report an outbreak of urinary tract infections (UTIs) caused by *Myroides odoratimimus*, which occurred in the largest clinical hospital in western Romania.

**Patients and methods:** From June to August 2017, four strains of *M. odoratimimus* were isolated from the urine samples of patients hospitalized in the urology, diabetes, and surgery departments. Hospital records of all patients whose urine cultures were positive for *M. odoratimimus* were reviewed retrospectively. We also reviewed the cases reported in the literature.

**Results:** All UTIs, except one, were hospital-acquired infections. All patients with *M. odoratimimus* UTIs were immunocompromised. Three patients underwent urinary catheterization with a Foley’s catheter upon admission in the emergency department and one presented for replacement of ureterostomy tubes. All *Myroides* isolates were resistant to almost all the tested antibiotics. Two patients were successfully treated with tigecycline and one was receiving antimicrobial treatment for another infection at the time of isolation of the microorganism.

**Conclusion:** Although *M. odoratimimus* is an uncommon pathogen, clinicians should be aware of its ability to cause UTI outbreaks, especially in the immunocompromised population. Due to its multi-drug resistance, it is important to rapidly identify *Myroides* spp. in order to choose the best treatment regimen.

**Keywords:** *Myroides odoratimimus*, urinary tract infection, resistance, outbreak

**Introduction**

The *Myroides* genus was created in 19961 for *Flavobacterium odoratum* species which were excluded from the *Flavobacterium* genus by Bernardet et al2 due to important genomic and phenotypic differences. The new *Myroides* genus comprises two species, *Myroides odoratus* (former *F. odoratum*) and *Myroides odoratimimus*, which are Gram-negative rods, strictly aerobic, non-motile, with yellow pigmentation and a characteristic fruity odor.1

*Myroides* spp. are commonly found in environmental sources, particularly in soil3,4 and water,5,6 but have also been isolated from seafood products,7 meat-processing plants,8 and the gut of adult flesh flies.9

Members of the *Myroides* genus also behave as low-grade opportunistic pathogens, causing community-10 or hospital-acquired11–13 infections. *Myroides* spp. have been found to be responsible for cases of soft tissue infections,10,14 septic shock and pneumonia,14,15 systemic infections,11,12,16,17 necrotizing fasciitis,18 urinary tract infections (UTIs),19,20 or erysipelas.16
We report an outbreak of UTIs caused by *M. odoratimimus* in a Romanian hospital, which is, to our knowledge, the first outbreak recorded in our country and the third described in the literature to date.\(^{19,20}\)

**Patients and methods**

**Study population**

During a 3-month period (from June to August 2017), four isolates of *Myroides* spp. were identified among the 333 positive urine cultures analyzed in the Microbiology Laboratory of the “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, Romania. This institution is a 1,173-bed, tertiary care, university-affiliated hospital providing health care services for the western region of Romania. The study was approved by the Hospital Ethics Committee. Patients signed an informed consent upon admission, which included the fact that data recorded during hospitalization could be used for future research studies.

**Microbiological analysis and data collection**

All isolates were first identified as *Myroides* spp. using the VITEK\(^\text{®}\) 2 GN ID cards (BioMérieux, Marcy l’Etoile, France) and then confirmed as *M. odoratimimus* by the matrix assisted laser desorption/ionization-time of flight mass spectrometry (Bruker Daltonics, Bremen, Germany) system.

Antimicrobial susceptibility tests (AST) were performed using the VITEK 2 GN AST-N222 cards by determination of the minimum inhibitory concentration (MIC) and classification into resistance phenotypes. The following antimicrobial agents were tested: ticarcillin, piperacillin, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, amikacin, gentamicin, tobramycin, ciprofloxacin, pefloxacin, minocycline, colistin, and trimethoprim–sulfamethoxazole. MIC results were interpreted according to the Clinical and Laboratory Standards Institute criteria. Extensive drug resistance was defined as acquired resistance to at least one agent in all, but two or fewer antimicrobial categories.\(^{21}\)

Hospital records of all patients with positive *M. odoratimimus* urine cultures were reviewed retrospectively. The collected data included the demographic characteristics of the patients, comorbidities, and the presence of an indwelling urinary catheter. The antimicrobial treatment and the clinical outcomes were individually reviewed.

**Results**

Four cases of *M. odoratimimus*-positive urine cultures were identified in the Microbiology Laboratory of the “Pius Brînzeu” Emergency Clinical County Hospital, Timișoara, between June and August 2017. The isolates were recovered from patients admitted to the departments of urology (two cases), surgery (one case), and diabetes (one case), respectively.

Demographics and clinical data of the patients are shown in Table 1. Three (75%) patients were males and one (25%) was a female. The mean age was 56 years (range 36–72). The patient hospitalized in the surgery department (C1) had a case history of kidney transplantation for chronic glomerulonephritis and was under immunsuppressive treatment. He was also suffering from anal condylomatosis, for which he underwent multiple surgical interventions (the last one 4 days before presentation at the emergency room). He was admitted for abdominal pain and anuria. The female patient (C2) had diabetes mellitus and was hospitalized for diabetic ketoacidosis. One of the patients admitted to the urology department (C3) had a case history of transurethral resection of the prostate for benign prostatic hyperplasia and was suffering from COPD, for which he was on long-term corticosteroid treatment; he was admitted for acute urinary retention. The other patient from the urology department (C4) had undergone a radical cystectomy with bilateral cutaneous ureterostomy for a muscle-invasive bladder cancer 3 months earlier. He was admitted for the replacement of the ureterostomy tubes.

Three cases (C1–C3) underwent urinary catheterization with a Foley’s catheter on presentation at the emergency room (one for acute urinary retention and two for accurate monitoring of urinary output). These patients also complained of symptoms characteristic of UTI (fever, flank pain, costovertebral angle tenderness, or pelvic discomfort) and their urinalysis showed the presence of nitrites, leukocyte esterase, and more than five white blood cells per high-power field. All these cases were hospital-acquired UTIs, with a mean duration of hospitalization of 11 days (range 2–23) before isolation of the uropathogen.

AST and the determination of MICs revealed that all *M. odoratimimus* isolates were sensitive only to minocycline and were resistant to beta-lactams (including extended-spectrum cephalosporins and beta-lactamase inhibitors), monobactams, carbapenems, aminoglycosides, fluoroquinolones, polymyxins, and sulfonamides. One isolate demonstrated intermediate susceptibility to piperacillin/tazobactam. MICs of the antimicrobial agents are shown in Table 2.

Two patients (C2 and C3) received tigecycline for the treatment of UTIs with a good clinical response. One patient (C1) had been receiving antibiotic treatment for a pelvic...
Extensively drug-resistant Myroides odoratimimus UTIs

abscess (with imipenem, amikacin, colistin) for 22 days at the time the microorganism was isolated in urine, with a favorable outcome.

In accordance with the European Association of Urology guidelines,\textsuperscript{22} C4 did not receive antibiotic treatment as no symptoms were present in this patient.

Discussion

Myroides spp. are Gram-negative bacilli frequently encountered in the environment, usually in sources such as water and soil.\textsuperscript{3,4} They are uncommon pathogens in humans, having been reported as causing opportunistic infections, most often in severely immunocompromised hosts.\textsuperscript{11,23–25} Only rarely have they been identified in immunocompetent patients.\textsuperscript{10,14}

The present outbreak of UTIs due to \textit{M. odoratimimus} is the third described in the literature to date. We reviewed the cases reported in literature to date (Table 3). Holmes et al\textsuperscript{26} first reported these isolates from UTIs, describing 18 strains of \textit{F. odoratum} isolated from urine.\textsuperscript{27} \textit{M. odoratimimus} has been previously identified as an etiologic agent for UTIs in two nosocomial outbreaks among urologic patients.\textsuperscript{19,20} Ktari et al\textsuperscript{19} reported seven cases of UTIs due to \textit{M. odoratimimus} in the urology unit of a Tunisian hospital, all of them (except one) in patients who underwent endourological surgeries and had urinary calculi. The available clinical data in the Turkish report of Yağcı et al\textsuperscript{20} covering a 3-year period showed that patients with \textit{F. odoratum} UTIs were catheterized and had either neoplasia of the urinary tract or urinary calculi. In the current report, two of the four patients had urological comorbidities (transurethral resection of the prostate for benign prostatic hyperplasia and cystectomy with bilateral cutaneous ureterostomy for bladder cancer). The four \textit{M. odoratimimus} cases reported in this study were urinary sources only, although it appears this pathogen may be potentially isolated in other sites. A recently published Indian case report discussed isolating \textit{M. odoratimimus} from both urine and blood cultures of a patient with anaplastic astrocytoma.\textsuperscript{28}

All our patients with \textit{M. odoratimimus} UTIs had an indwelling urinary device and all except one (C4) have been hospitalized for lengthy periods. The most important predisposing factor for hospital-acquired UTIs is urinary catheterization, which reduces host defense mechanisms and offers easier access of germs to the bladder.\textsuperscript{29} It is possible that C4 acquired the uropathogen prior to admission, most probably 3 months earlier during his previous hospitalization for radical cystectomy, when he had ureterostomy tubes placed.

We suspect that the current outbreak arose in the emergency room where patients underwent urinary catheterization,

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline
Case no., age (years)/gender & Department, admission date & Collection date & Days of hospitalization & Comorbidities & Presence of an indwelling device & Prior antibiotic treatment & Type of infection & Treatment for \textit{Myroides} UTI & Outcome & Type of infection & Table 1 Clinical characteristics and treatment of the four cases of UTIs due to \textit{Myroides odoratimimus}
\end{tabular}
\end{table}

\textbf{Case 1}: 36/M

\textbf{Department, admission date}: Surgery, May 30, 2017

\textbf{Collection date}: June 22, 2017

\textbf{Days of hospitalization}: 43

\textbf{Comorbidities}: Pelvic abscess, condylomatosis, kidney transplantation, hepatitis B

\textbf{Presence of an indwelling device}: Urethro-vesical catheterization

\textbf{Prior antibiotic treatment}: Imipenem, amikacin, colistin

\textbf{Type of infection}: UTI

\textbf{Treatment for \textit{Myroides} UTI}: Imipenem, amikacin, colistin

\textbf{Outcome}: Cured

\textbf{Case 2}: 59/F

\textbf{Department, admission date}: Diabetes, June 19, 2017

\textbf{Collection date}: June 27, 2017

\textbf{Days of hospitalization}: 9

\textbf{Comorbidities}: Diabetes mellitus, above-knee left amputation for PAD, obesity, hypertension

\textbf{Presence of an indwelling device}: Urethro-vesical catheterization

\textbf{Prior antibiotic treatment}: None

\textbf{Type of infection}: UTI

\textbf{Treatment for \textit{Myroides} UTI}: None

\textbf{Outcome}: UTI

\textbf{Case 3}: 72/M

\textbf{Department, admission date}: Urology, June 24, 2017

\textbf{Collection date}: June 26, 2017

\textbf{Days of hospitalization}: 10

\textbf{Comorbidities}: TUR-P for BPH, BNI for bladder neck obstruction, COPD

\textbf{Presence of an indwelling device}: Urethro-vesical catheterization

\textbf{Prior antibiotic treatment}: Tigecycline

\textbf{Type of infection}: UTI

\textbf{Treatment for \textit{Myroides} UTI}: Tigecycline

\textbf{Outcome}: Good clinical response

\textbf{Case 4}: 57/M

\textbf{Department, admission date}: Urology, August 3, 2017

\textbf{Collection date}: August 3, 2017

\textbf{Days of hospitalization}: 2

\textbf{Comorbidities}: Radical cystectomy for high grade papillary urothelial carcinoma stage pT2, obesity, hypertension

\textbf{Presence of an indwelling device}: None

\textbf{Prior antibiotic treatment}: None

\textbf{Type of infection}: Bladder colonization

\textbf{Treatment for \textit{Myroides} UTI}: None

\textbf{Outcome}: Favorable

Abbreviations: BNI, bladder neck incision; BPH, benign prostatic hyperplasia; PAD, peripheral artery disease; TUR-P, transurethral resection of prostate; UTI, urinary tract infection.
Table 2  In vitro susceptibility testing of the Myroides odoratimimus isolates

| Antibiotic                  | C1 MIC value (µg/mL) | Interpretation | C2 MIC value (µg/mL) | Interpretation | C3 MIC value (µg/mL) | Interpretation | C4 MIC value (µg/mL) | Interpretation |
|-----------------------------|----------------------|----------------|----------------------|----------------|----------------------|----------------|----------------------|----------------|
| Ticarcillin                 | ≥128                 | R              | ≥128                 | R              | ≥128                 | R              | ≥128                 | R              |
| Piperacillin                | ≥128                 | R              | ≥128                 | R              | ≥128                 | R              | ≥128                 | R              |
| Piperacillin/tazobactam     | 64                   | I              | ≥128                 | R              | ≥128                 | R              | ≥128                 | R              |
| Ceftazidime                 | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              |
| Cefepime                    | 32                   | R              | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              |
| Aztreonam                   | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              |
| Imipenem                    | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              |
| Meropenem                   | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              |
| Amikacin                    | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              | ≥64                  | R              |
| Gentamicin                  | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              |
| Tobramycin                  | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              |
| Ciprofloxacin               | ≥4                   | R              | ≥4                   | R              | ≥4                   | R              | ≥4                   | R              |
| Pefloxacin                  | 8                    | R              | 8                    | R              | 8                    | R              | 16                   | R              |
| Minocycline                 | 2                    | S              | 2                    | S              | 2                    | S              | 1                    | S              |
| Colistin                    | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              | ≥16                  | R              |
| Trimethoprim–  | ≥320                 | R              | ≥320                 | R              | ≥320                 | R              | ≥320                 | R              |

Interpretation: S, susceptible; I, intermediate; R, resistant.

Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.

although the normal hospital environmental screening did not reveal any contamination with Myroides spp. In many cases, the source of Myroides spp. infection remains unknown, although water in the hospital environment is often suspected of carrying the microorganism.20,30

In the current outbreak, all the patients who developed M. odoratimimus UTIs were immunocompromised. Diabetes mellitus, chronic corticosteroid treatment for COPD, and liver cirrhosis have all been previously identified as causes of immunodepression in patients with Myroides spp. infections.11,23-25

Myroides spp. are known to be resistant to a wide range of antimicrobial agents, including beta-lactams, monobactams, carbapenems, and aminoglycosides.27 The resistance to beta-lactams is due to the production of chromosome-encoded metallo-beta-lactamases, TUS-1 for M. odoratus and MUS-1 for M. odoratimimus.13 Due to their multiple antibiotic resistance mechanisms, a fast and reliable identification method for Myroides spp. is needed. Schrottner et al showed that the VITEK 2 diagnostic system is suitable for identifying bacteria at the genus level, but cannot differentiate between species. In contrast to this, matrix assisted laser desorption/ionization-time of flight mass spectrometry and 16S rDNA are methods capable of distinguishing between M. odoratus and M. odoratimimus.12

Choosing the appropriate antimicrobial treatment for Myroides infections can be quite challenging because of the limited clinical experience. All M. odoratimimus isolates reported in the present paper were extensive drug resistance strains, sensitive only to minocycline and resistant to all the other tested antimicrobials. Two of our patients were successfully treated with tigecycline. Previous studies reported quinolones combined with rifampicin as optimal therapeutic regimens for treating M. odoratimimus UTI.14 Other sites of Myroides spp. infections benefited from treatment with cotrimoxazole, meropenem, or piperacillin/tazobactam,12,14,17 with favorable clinical responses.

One limitation of the present study could be the lack of pulsed-field gel electrophoresis tests to confirm the outbreak and trace the source of genetically related strains.

Conclusion

Although Myroides spp. are uncommon pathogens, clinicians should be aware of the ability of M. odoratimimus to cause prolonged UTI outbreaks, especially in the immunocompromised population. It is important to identify Myroides spp. infections rapidly in order to choose the best therapeutic regimen, considering the wide range of antibiotic resistance of these microorganisms.

Acknowledgments

We gratefully acknowledge the contribution of Bioclinica Laboratories for Myroides odoratimimus identification on matrix assisted laser desorption/ionization-time of flight mass spectrometry system. Part of this paper was presented at the 10th National Conference of Microbiology and Epidemiology, from Bucharest, Romania, Nov 02–04, 2017.
## Extensively drug-resistant Myroides odoratimimus UTIs

### Table 3

Reported cases of *Myroides* spp. strains isolated from the urine, as found in the USA National Library of Medicine (PubMed) database (May 12, 2017)

| Case no. | Gender/age (years) | Clinical condition/indwelling device | Antibiotic resistance status | Treatment for *Myroides* UTIs | Outcome | Report/year/reference |
|----------|--------------------|-------------------------------------|-------------------------------|--------------------------------|---------|----------------------|
| 1        | M/66               | Bilateral hydronephrosis, bilateral ureteric stones/left DJ stent | Resistant to all beta-lactam and non-beta-lactam antibiotics, including imipenem, vancomycin, ciprofloxacin, chloramphenicol | Imipenem, colistin | Failure | Ktari et al/2012/19 |
| 2        | M/44               | Bilateral hydronephrosis, bilateral ureteric stones, left kidney stone/bilateral DJ stent | No treatment (bladder colonization) | No treatment (bladder colonization) | Favorable | Ktari et al/2012/19 |
| 3        | M/44               | Left ureteric stone/left DJ stent | No treatment (bladder colonization) | No treatment (bladder colonization) | Favorable | Ktari et al/2012/19 |
| 4        | M/47               | BPH, bladder calculi | | No treatment (bladder colonization) | Favorable | Ktari et al/2012/19 |
| 5        | M/77               | Right hydronephrosis, right ureteric stone/right DJ stent | Rifampicin + ciprofloxacin | Rifampicin + ciprofloxacin | Cured | Ktari et al/2012/19 |
| 6        | M/65               | BPH, bladder calculi, prostatitis | Rifampicin + ciprofloxacin | Rifampicin + ciprofloxacin | Cured | Ktari et al/2012/19 |
| 7        | M/80               | Bladder cancer | Rifampicin + ciprofloxacin | Rifampicin + ciprofloxacin | Cured | Ktari et al/2012/19 |
| 8–11 (four cases) | ND/ND            | Neoplasia of the urinary tract/catheterization | Resistant to all 12 antimicrobial agents tested (amikacin, aztreonam, cefoperazone, cefazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, tetracycline, tobramycin, trimethoprim–sulfamethoxazole) | ND | ND | Yağcı et al/2000/20 |
| 12–20 (nine cases) | ND/ND            | Urinary calculi/catheterization | ND | ND | ND | Yağcı et al/2000/20 |
| 21–29 (nine cases) | ND/ND           | ND | piperacillin, tetracycline, tobramycin, trimethoprim–sulfamethoxazole | ND | ND | Yağcı et al/2000/20 |
| 30       | F/48               | Cystitis (contaminant) | Fully resistant to clinically obtainable levels of streptomycin, kanamycin, gentamicin, tobramycin, amikacin, ampicillin, carbenicillin, chloramphenicol, tetracycline, polymyxin B, and erythromycin | Furadantin | ND | Holmes et al/1979/27 |
| 31       | F/59               | ND (contaminant) | ND | ND | ND | Holmes et al/1979/27 |
| 32       | F/ND               | Urinary retention (not clinically significant) | ND | ND | ND | Holmes et al/1979/27 |
| 33       | ND/ND              | Not known | ND | ND | ND | Holmes et al/1979/27 |
| 34       | F/67               | Total cystectomy, ileal loop urethrotomy (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 35       | M/48               | Renal insufficiency, pyelonephritis, renal calculi (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 36       | M/54               | ND (very scanty numbers) | ND | ND | ND | Holmes et al/1979/27 |
| 37       | M/87               | ND (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 38       | M/46               | ND (Mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 39       | M/59               | ND (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 40       | F/ND               | ND (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 41       | M/67               | Multideficiency syndrome, pyelonephritis, liver disease (mixed culture) | ND | ND | ND | Holmes et al/1979/27 |
| 42       | M/38               | Relapsing UTIs, bladder carcinoma | ND | ND | ND | Holmes et al/1979/27 |
| 43       | ND/ND              | ND | ND | ND | ND | Holmes et al/1979/27 |
| 44       | M/ND               | Syringomyelia/indwelling catheter | ND | ND | ND | Holmes et al/1979/27 |
| 45       | F/ND               | Relapsing urinary infection, renal insufficiency, hypertension | ND | ND | ND | Holmes et al/1979/27 |
| 46       | M/19               | Spina bifida/permanent catheter | ND | ND | ND | Holmes et al/1979/27 |
| 47       | ND/ND              | ND | ND | ND | ND | Holmes et al/1979/27 |

**Abbreviations:** BPH, benign prostatic hyperplasia; DJ, double-J; ND, not described; UTI, urinary tract infection.
Disclosure

The authors report no conflicts of interest in this work.

References

1. Vancanneyt M, Segers P, Torck U, et al. Reclassification of Flavobacterium odoratum (Stutzer, 1929) strains to a new genus, Myroides, as Myroides odoratus comb. nov. and Myroides odoratimimus sp. nov. Int J Syst Bacteriol. 1996;46(4):926–932.

2. Bernardet JF, Segers P, Vancanneyt M, Berthe F, Kersters K, Vandamme P. Cutting a Gordian knot: emended classification and description of the genus Flavobacterium, emended description of the family Flavobacteriaceae, and proposal of Flavobacterium hydatis nom. nov. (basoynm, Cytophaga aquatilis Strohl and Tait 1978). Int J Syst Bacteriol. 1996;46(1):128–148.

3. Ram H, Kumar A, Thomas L, Dastager SG, Mawlankar R, Singh VP. Myroides indicus sp. nov., isolated from garden soil. Int J Syst Evol Microbiol. 2015;65(11):4008–4012.

4. Yang Q, Wang R, Ren S, Szoboszlai M, Moe LA. Practical survey on antibiotic-resistant bacterial communities in livestock manure and manure-amended soil. J Environ Sci Health B. 2016;51(1):14–23.

5. Vaz-Moreira I, Varela AR, Pereira TV, Fochat RC, Manaia CM. Multidrug resistance in quinolone-resistant gram-negative bacteria isolated from hospital effluent and the municipal wastewater treatment plant. Microb Drug Resist. 2016;22(2):155–162.

6. Maneerat S, Nitoda T, Kanzaki H, Kawai F. Bile acids are new products of a marine bacterium, Myroides sp. strain SM1. Appl Microbiol Biotechnol. 2008;77(5):679–683.

7. Morrison BJ, Rubin JE. Carbapenemase producing bacteria in the food supply escaping detection. PLoS One. 2015;10(5):e0126717.

8. Li L, Ye L, Zhang S, Meng H. Isolation and identification of aerobic bacteria carrying tetracycline and sulfonamide resistance genes obtained from a meat processing plant. J Food Sci. 2016;81(6):M1480–M1484.

9. Dharne MS, Gupta AK, Rangrez AY, Ghate HV, Patole MS, Shouche YS. Antibacterial activities of multi drug resistant Myroides odoratimimius bacteria isolated from adult flesh flies (Diptera: sarcophagidae) are independent of metallo beta-lactamase gene. Braz J Microbiol. 2008;39(2):397–404.

10. Maraki S, Sarchianaki E, Barbagadakis S. Myroides odoratimimius soft tissue infection in an immunocompetent child following a pig bite: case report and literature review. Braz J Infect Dis. 2012;16(4):390–392.

11. Endicott-Yazdani TR, Dhiman N, Benavides R, Spak CW. Myroides odoratimimus bacteremia in a diabetic patient. Proc (Bayl Univ Med Cent). 2015;28(3):342–343.

12. Elantamilian D, Lyngdoh VW, Choudhury B, Khyriem AB, Rajbongshi J. Septicaemia caused by Myroides spp.: a case report. JMM Case Rep. 2015;2(5):1–4.

13. Mammori H, Bellais S, Nordmann P. Chromosome-encoded beta-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odoratimimus (formerly Flavobacterium odoratum), new members of the lineage of molecular subclass B1 metalloenzymes. Antimicrob Agents Chemother. 2002;46(11):3561–3567.

14. Benedetti P, Rassu M, Pavan G, Sefon A, Pellizzer G. Septic shock, pneumonia, and soft tissue infection due to Myroides odoratimimus: report of a case and review of Myroides infections. Infection. 2011;39(2):161–165.

15. Lahmer T, Beitz A, Ehmer U, Schmid RM, Huber W. Septic shock due to Myroides odoratus in a medical intensive care unit patient with severe necrotising pancreatitis. Anaesth Intensive Care. 2016;44(2):298–299.

16. Willems P, Muller J, Verhaegen J, Saegeman V, Desmet S. How to treat a fulminant erysipelas and sepsis caused by Myroides odoratimimus: case report and literature review. Acta Clin Belg. 2017;72(5):331–335.

17. Beharrysingh R. Myroides bacteremia: a case report and concise review. Infect Dis Cases. 2017;8:34–36.

18. Crum-Cianflone NF, Matson RW, Ballon-Landa G. Fatal case of necrotizing fasciitis due to Myroides odoratus. Infection. 2014;42(5):931–935.

19. Ktari S, Mnf B, Koubia M, et al. Nosocomial outbreak of Myroides odoratimimus urinary tract infection in a Tunisian hospital. J Hosp Infect. 2012;80(1):77–81.

20. Yağcı A, Cericlioğlu N, Kaufmann ME, et al. Molecular typing of Myroides odoratimimus Flavobacterium odoratum urinary tract infections in a Turkish hospital. Eur J Clin Microbiol Infect Dis. 2000;19(9):731–732.

21. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.

22. Bonkat G, Pickard R, Bartlett D, et al. Guidelines on urological infections. In: EAU Guidelines. European Association of Urology. 2017. Available from: https://uroweb.org/guideline/urological-infections/.

23. Motwai B, Krezolek D, Symeonides S, Khayr W. Myroides odoratus cellulitis and bacteremia: a case report. Infect Dis Clin Pract. 2004;12:343–344.

24. Bachmeyer C, Entressengle H, Krosrotehrani K, et al. Cellulitis due to Myroides odoratimimus in a patient with alcoholic cirrhosis. Clin Exp Dermatol. 2008;33(1):97–98.

25. Bachman KH, Sewell DL, Straubbaugh LJ. Recurrent cellulitis and bacteremia caused by Flavobacterium odoratum. Clin Infect Dis. 1996;22(6):1112–1113.

26. Holmes B, Snell JJS, Lapage SP. Revised description from clinical isolates, of Flavobacterium odoratum Stutzer and Kwaschnina 1929, and designation of the neotype strain. Int J Syst Bacteriol. 1977;27(4):330–336.

27. Holmes B, Snell JJ, Lapage SP. Flavobacterium odoratum: a species resistant to a wide range of antimicrobial agents. J Clin Pathol. 1979;32(1):73–77.

28. Ranjan M, Karade S, Rahi P, Singh SP, Sen S. Urosepsis due to multi drug resistant Myroides odoratimimus: a case report. Int J Curr Microbiol App Sci. 2017;6(8):1930–1935.

29. Hooton TM, Bradley SF, Cardenas DD, et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663.

30. Hugo CJ, Bruun B, Jooste PJ. The genera Empedobacter and Myroides. In: Dworkin M, Fallow S, Rosenberg E, Schleifer KH, Stackebrandt E, editors. The Prokaryotes. New York, NY, USA: Springer; 2006:532–538.

31. Hu SH, Yuan SX, Qu H, et al. Antibiotic resistance mechanisms of Myroides sp. J Zhejiang Univ Sci B. 2010;11:625–663.

32. Yang Q, Wang R, Ren S, Szoboszlai M, Moe LA. Practical survey on antibiotic-resistant bacterial communities in livestock manure and manure-amended soil. J Environ Sci Health B. 2016;51(1):14–23.

33. Vaz-Moreira I, Varela AR, Pereira TV, Fochat RC, Manaia CM. Multidrug resistance in quinolone-resistant gram-negative bacteria isolated from hospital effluent and the municipal wastewater treatment plant. Microb Drug Resist. 2016;22(2):155–162.

34. Maraki S, Sarchianaki E, Barbagadakis S. Myroides odoratimimus soft tissue infection in an immunocompetent child following a pig bite: case report and literature review. Braz J Infect Dis. 2012;16(4):390–392.

35. Endicott-Yazdani TR, Dhiman N, Benavides R, Spak CW. Myroides odoratimimus bacteremia in a diabetic patient. Proc (Bayl Univ Med Cent). 2015;28(3):342–343.

36. Elantamilian D, Lyngdoh VW, Choudhury B, Khyriem AB, Rajbongshi J. Septicaemia caused by Myroides spp.: a case report. JMM Case Rep. 2015;2(5):1–4.

37. Mammori H, Bellais S, Nordmann P. Chromosome-encoded beta-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odoratimimus (formerly Flavobacterium odoratum), new members of the lineage of molecular subclass B1 metalloenzymes. Antimicrob Agents Chemother. 2002;46(11):3561–3567.
